Highlights DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Delayed Nasdaq Other stock markets 12:02:14 18/05/2024 am IST			5-day change	1st Jan Change
3.17 ^USD	0.00%		+1.60%	+11.62%

09/05	Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
17/04	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	18/04	MT
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	18/04	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Top Premarket Gainers	25/23/25	MT
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
DiaMedica Therapeutics Announces US FDA's Removal of Clinical Hold on Phase 2/3 Trial for Ischemic Stroke Treatment DM199	21/23/21	MT
DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke	21/23/21	CI
Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study	23/23/23	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
DiaMedica Therapeutics Inc. Announces Update on Clinical Developments ReMEDy2 Phase 2/3 Trial	29/23/29	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
DiaMedica Therapeutics Inc. Provides Update on Remedy2 Trial	27/22/27	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/22/11	CI
DiaMedica Therapeutics Says Phase 2/3 Trial of Stroke Drug Candidate on Clinical Hold; Stock Sinks 40% After Hours	07/22/07	MT
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199	07/22/07	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	04/22/04	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
DiaMedica Therapeutics Inc. Provides a Business Update	15/22/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Highlights

Filters